NO20013371L - Ekspresjon og eksport av anti-fedmeproteiner som Fc- fusjonsproteiner - Google Patents
Ekspresjon og eksport av anti-fedmeproteiner som Fc- fusjonsproteinerInfo
- Publication number
- NO20013371L NO20013371L NO20013371A NO20013371A NO20013371L NO 20013371 L NO20013371 L NO 20013371L NO 20013371 A NO20013371 A NO 20013371A NO 20013371 A NO20013371 A NO 20013371A NO 20013371 L NO20013371 L NO 20013371L
- Authority
- NO
- Norway
- Prior art keywords
- proteins
- fusion proteins
- nucleotide sequences
- export
- expression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Endocrinology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Det beskrives nukleotidsekvenser, for eksempel DNA- eller RNA-sekvenser, som koder for et immunglobulin Fc-leptin fusjonsprotein. Nukleotidsekvensene kan innsettes i en egnet ekspresjonsvektor og uttrykkes i pattedyrceller. Det beskrives også en familie av immunglobulin Fc-leptin fusjonsproteiner som kan fremstilles ved ekspresjon av slike nukleotidsekvenser. Fremgangsmåter for anvendelse av slike nukleotidsekvenser og fusjonsproteiner til behandling av tilstander som lindres ved administreringen av leptin, er også beskrevet.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11507999P | 1999-01-07 | 1999-01-07 | |
PCT/US2000/000352 WO2000040615A2 (en) | 1999-01-07 | 2000-01-07 | EXPRESSION AND EXPORT OF ANTI-OBESITY PROTEINS AS Fc FUSION PROTEINS |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20013371D0 NO20013371D0 (no) | 2001-07-06 |
NO20013371L true NO20013371L (no) | 2001-09-04 |
Family
ID=22359200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20013371A NO20013371L (no) | 1999-01-07 | 2001-07-06 | Ekspresjon og eksport av anti-fedmeproteiner som Fc- fusjonsproteiner |
Country Status (16)
Country | Link |
---|---|
US (1) | US20040053366A1 (no) |
EP (1) | EP1141013A2 (no) |
JP (1) | JP2002534962A (no) |
KR (1) | KR20020007287A (no) |
CN (1) | CN1341121A (no) |
AU (1) | AU778939B2 (no) |
BR (1) | BR0007414A (no) |
CA (1) | CA2356401A1 (no) |
CZ (1) | CZ20012406A3 (no) |
HU (1) | HUP0105090A2 (no) |
ID (1) | ID30327A (no) |
MX (1) | MXPA01006922A (no) |
NO (1) | NO20013371L (no) |
SK (1) | SK9432001A3 (no) |
WO (1) | WO2000040615A2 (no) |
ZA (1) | ZA200105352B (no) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1037927B1 (en) | 1997-12-08 | 2004-05-19 | Lexigen Pharmaceuticals Corp. | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
CA2328076C (en) * | 1998-04-15 | 2009-10-06 | Lexigen Pharmaceuticals Corporation | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
MXPA02001417A (es) * | 1999-08-09 | 2002-08-12 | Lexigen Pharm Corp | Complejos multiples de citosina-anticuerpo. |
US20050202538A1 (en) * | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
ES2269366T3 (es) | 2000-02-11 | 2007-04-01 | Merck Patent Gmbh | Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos. |
DE60129695T2 (de) * | 2000-06-29 | 2008-06-05 | Merck Patent Gmbh | Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme |
US7189830B2 (en) * | 2001-02-19 | 2007-03-13 | Merck Patent Gmbh | Anti-KSA/IL-2 fusion proteins with reduced immunogenicity |
KR100899970B1 (ko) | 2001-02-19 | 2009-05-28 | 메르크 파텐트 게엠베하 | T-세포 에피토프의 동정 방법 및 감소된 면역원성을 갖는분자의 제조를 위한 용도 |
CN1330664C (zh) * | 2001-03-07 | 2007-08-08 | 默克专利有限公司 | 用于含杂合同种型抗体部分的蛋白质的表达技术 |
US6992174B2 (en) * | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
CN100503639C (zh) * | 2001-05-03 | 2009-06-24 | 默克专利有限公司 | 重组肿瘤特异性抗体及其应用 |
MXPA04005266A (es) * | 2001-12-04 | 2004-10-11 | Merck Patent Gmbh | Inmunocitocinas con selectividad modulada. |
US7169904B2 (en) * | 2002-12-17 | 2007-01-30 | Emd Lexigen Research Center Corp. | Immunocytokine sequences and uses thereof |
US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
EP1697415A1 (en) | 2003-11-12 | 2006-09-06 | Biogen Idec MA Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
CN103212084B (zh) | 2003-11-13 | 2018-07-13 | 韩美科学株式会社 | 含有免疫球蛋白fc区作为载体的药物组合物 |
US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
WO2005063820A2 (en) * | 2003-12-30 | 2005-07-14 | Merck Patent Gmbh | Il-7 fusion proteins |
DK1699821T3 (da) * | 2003-12-31 | 2012-07-16 | Merck Patent Gmbh | Fc-ERYTHROPOIETIN-FUSIONSPROTEIN MED FORBEDREDE FARMAKOKINETIKKER |
CA2552590A1 (en) | 2004-01-05 | 2005-07-21 | Emd Lexigen Research Center Corp. | Interleukin-12 targeted to oncofoetal fibronectin |
WO2005070967A2 (en) * | 2004-01-22 | 2005-08-04 | Merck Patent Gmbh | Anti-cancer antibodies with reduced complement fixation |
US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
US7589179B2 (en) * | 2004-12-09 | 2009-09-15 | Merck Patent Gmbh | IL-7 variants with reduced immunogenicity |
ES2408704T3 (es) | 2005-01-05 | 2013-06-21 | Biogen Idec Ma Inc. | Moléculas de unión a Cripto |
US7566456B2 (en) * | 2005-06-23 | 2009-07-28 | Haiming Chen | Allergen vaccine proteins for the treatment and prevention of allergic diseases |
KR20080050576A (ko) * | 2005-07-29 | 2008-06-09 | 앰프로틴 코포레이션 | 키메릭 치료제 |
US8227408B2 (en) * | 2005-09-07 | 2012-07-24 | Neurotez, Inc. | Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology |
US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
EP1801121A1 (en) * | 2005-12-23 | 2007-06-27 | CONARIS research institute AG | Soluble gp130 molecule variants useful as a medicament |
PT2270050E (pt) | 2005-12-30 | 2013-09-12 | Merck Patent Gmbh | Anticorpos anti-cd19 com imunogenicidade reduzida |
ES2384055T3 (es) | 2005-12-30 | 2012-06-28 | Merck Patent Gmbh | Variantes de la interleucina-12p40 con estabilidad mejorada |
US7846434B2 (en) * | 2006-10-24 | 2010-12-07 | Trubion Pharmaceuticals, Inc. | Materials and methods for improved immunoglycoproteins |
US20080227669A1 (en) * | 2007-03-12 | 2008-09-18 | Halliburton Energy Services, Inc. | Corrosion-inhibiting additives, treatment fluids, and associated methods |
CA2725143A1 (en) | 2008-05-21 | 2009-11-26 | Neurotez, Inc. | Methods for treating progressive cognitive disorders related to neurofibrillary tangles |
KR20120024529A (ko) | 2008-11-04 | 2012-03-14 | 니콜라오스 테자프시디스 | 신경섬유 매듭 및 아밀로이드 베타의 축적으로부터 기인하는 진행성 인지 기능 장애의 치료용 렙틴 조성물 및 치료 방법 |
CA2759333A1 (en) | 2009-04-22 | 2010-10-28 | Merck Patent Gmbh | Antibody fusion proteins with modified fcrn binding sites |
CA2832581C (en) | 2011-04-08 | 2022-08-23 | Yumei Xiong | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
EP3626739A1 (en) | 2011-06-24 | 2020-03-25 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
BR112014018575A2 (pt) | 2012-01-26 | 2017-07-04 | Amgen Inc | polipetídeos de fator de diferenciação de crescimento 15 (gdf-15) |
PL2880170T3 (pl) | 2012-08-02 | 2017-02-28 | F.Hoffmann-La Roche Ag | SPOSÓB WYTWARZANIA ROZPUSZCZALNEGO FcR JAKO FUZJI Fc Z OBOJĘTNYM REGIONEM Fc IMMUNOGLOBULINY I JEGO ZASTOSOWANIA |
EP2880169B1 (en) | 2012-08-02 | 2017-05-17 | F. Hoffmann-La Roche AG | Method for producing monomeric and multimeric molecules and uses thereof |
SG11201500682WA (en) * | 2012-09-07 | 2015-02-27 | Sanofi Sa | Fusion proteins for treating a metabolic syndrome |
AU2014296107B2 (en) * | 2013-07-31 | 2018-07-26 | Amgen Inc. | Growth differentiation factor 15 (GDF-15) constructs |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
CA3014498A1 (en) | 2016-03-21 | 2017-09-28 | Children's Medical Center Corporation | Compositions and methods for inhibiting wnt signaling |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
US20180009869A1 (en) * | 2016-07-08 | 2018-01-11 | AskGene Pharma, Inc. | Fusion Protein Comprising Leptin and Methods for Producing and Using the Same |
EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
PE20201350A1 (es) | 2018-04-09 | 2020-11-30 | Amgen Inc | Proteinas de fusion del factor de diferenciacion de crecimiento 15 |
US11197910B1 (en) * | 2020-08-19 | 2021-12-14 | Vitruviae LLC | Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6309853B1 (en) * | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US5541087A (en) * | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
WO1996031526A1 (en) * | 1995-04-06 | 1996-10-10 | Amylin Pharmaceuticals, Inc. | Anti-obesity agents |
GB9511935D0 (en) * | 1995-06-13 | 1995-08-09 | Smithkline Beecham Plc | Novel compound |
-
2000
- 2000-01-07 BR BR0007414-4A patent/BR0007414A/pt not_active IP Right Cessation
- 2000-01-07 CA CA002356401A patent/CA2356401A1/en not_active Abandoned
- 2000-01-07 AU AU26025/00A patent/AU778939B2/en not_active Ceased
- 2000-01-07 HU HU0105090A patent/HUP0105090A2/hu unknown
- 2000-01-07 WO PCT/US2000/000352 patent/WO2000040615A2/en not_active Application Discontinuation
- 2000-01-07 MX MXPA01006922A patent/MXPA01006922A/es unknown
- 2000-01-07 KR KR1020017008580A patent/KR20020007287A/ko not_active Application Discontinuation
- 2000-01-07 SK SK943-2001A patent/SK9432001A3/sk unknown
- 2000-01-07 EP EP00904239A patent/EP1141013A2/en not_active Withdrawn
- 2000-01-07 JP JP2000592323A patent/JP2002534962A/ja not_active Withdrawn
- 2000-01-07 ID IDW00200101488A patent/ID30327A/id unknown
- 2000-01-07 CN CN00804274A patent/CN1341121A/zh active Pending
- 2000-01-07 CZ CZ20012406A patent/CZ20012406A3/cs unknown
-
2001
- 2001-06-28 ZA ZA200105352A patent/ZA200105352B/en unknown
- 2001-07-06 NO NO20013371A patent/NO20013371L/no not_active Application Discontinuation
-
2003
- 2003-04-18 US US10/419,058 patent/US20040053366A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN1341121A (zh) | 2002-03-20 |
AU2602500A (en) | 2000-07-24 |
SK9432001A3 (en) | 2003-02-04 |
HUP0105090A2 (hu) | 2002-04-29 |
JP2002534962A (ja) | 2002-10-22 |
WO2000040615A3 (en) | 2000-11-23 |
US20040053366A1 (en) | 2004-03-18 |
ZA200105352B (en) | 2002-06-28 |
BR0007414A (pt) | 2001-10-16 |
EP1141013A2 (en) | 2001-10-10 |
CZ20012406A3 (cs) | 2002-03-13 |
CA2356401A1 (en) | 2000-07-13 |
MXPA01006922A (es) | 2002-04-24 |
ID30327A (id) | 2001-11-22 |
NO20013371D0 (no) | 2001-07-06 |
KR20020007287A (ko) | 2002-01-26 |
AU778939B2 (en) | 2004-12-23 |
WO2000040615A2 (en) | 2000-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20013371L (no) | Ekspresjon og eksport av anti-fedmeproteiner som Fc- fusjonsproteiner | |
PL352332A1 (en) | Expression and export of interferon-alpha proteins as fc fusion proteins | |
Moore et al. | EcoFlex: a multifunctional MoClo kit for E. coli synthetic biology | |
Didovyk et al. | Transcriptional regulation with CRISPR-Cas9: principles, advances, and applications | |
Worland et al. | Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast Saccharomyces cerevisiae | |
WO2000011033A3 (en) | Expression and export of angiostatin and endostatin as immunofusins | |
DE69935857D1 (de) | Expression eukarotischer peptide in pflanzenplastiden | |
AU2590901A (en) | Il-17 homologous polypeptides and therapeutic uses thereof | |
Whitaker et al. | Avoidance of truncated proteins from unintended ribosome binding sites within heterologous protein coding sequences | |
Senkevich et al. | Mapping vaccinia virus DNA replication origins at nucleotide level by deep sequencing | |
Olson et al. | Design, expression, and stability of a diverse protein library based on the human fibronectin type III domain | |
Lauer et al. | Cloning, nucleotide sequence, and engineered expression of Thermus thermophilus DNA ligase, a homolog of Escherichia coli DNA ligase | |
WO2002040668A3 (de) | Proteine und den proteinen zugrundeliegende dna-sequenzen mit funktion bei entzündungsereignissen | |
IL127297A0 (en) | Spruce budworm antifreeze proteins genes and methods of using same | |
DE69927249D1 (de) | Induzierendes alphavirengen- expressionssystem | |
DK0868435T3 (da) | Höjeffektivt vævsspecifikt forbindelsesindföringssystem ved anvendelse af streptavidin-protein A-fusionsprotein | |
Davis et al. | Generation of cDNA expression libraries enriched for in-frame sequences | |
HUP0304053A2 (hu) | Új expressziós vektorok és azok alkalmazása | |
Wang et al. | Parallel gene cloning and protein production in multiple expression systems | |
JP2004525618A5 (no) | ||
EP0763205A4 (en) | NUCLEIC ACID SEQUENCES REGULATING THE EXPRESSION OF LUNG SPECIFIC GENES | |
WO2002014369A3 (en) | Human kininogen d5 domain polypeptides and their use | |
Palmer et al. | Large-scale production of palindrome DNA fragments | |
WO2000064488A3 (en) | Somatic transgene immunization and related methods | |
WO2001032872A3 (en) | Twik potassium channel molecules and uses therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |